Search 

MaveriX Oncology is exploiting cancer and immune cell metabolism to discover and develop new targeted therapeutics that challenge the limitations of current chemotherapy and immunotherapy. The MaveriX technology approach is a multi-target, multi-asset small-molecule platform with potential first and best-in-class therapeutics designed for monotherapy and combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bring new and improved treatments to patients that suffer from cancer. Our lead program MVX5005 (E037) is well tolerated and exhibits broad, single- agent anti-tumor activity in preclinical mouse models of cancer. The unique mechanism-of-action targets cancer cells directly, induces immunogenic cell death while eradicating immune suppressive cells within the tumor microenvironment. E037 is currently completing IND-enabling studies targeting clinical entry Q3 2021. The company is currently raising capital and seeking strategic partnership opportunities to support clinical development to POC with differentiated platform expansion.

MaveriX Oncology, Inc., is a globally-orientated biotechnology company focused on the discovery and development of novel targeted small-molecule chemo-immunotherapies. The MaveriX technology approach exploits oncogenic and immunogenic targets that are over-expressed to a high frequency in the majority of solid tumors and hematological malignancies. This is a multi-target, multi-asset small-molecule platform technology with potential first and best-in-class therapeutics designed primarily for monotherapy activity in the clinic but with a robust mechanistic rational for combination chemotherapy and immunotherapy. Our experienced team of pharma executives is developing a proprietary pipeline of drug candidates with the goal of bringing new and improved treatments to patients suffering from cancer. Our lead program MVX5005 (E037) is well tolerated with broad single agent anti-tumor activity, can overcome key resistance mechanisms in cancer, and challenge the limitations of current chemotherapy and immunotherapy approaches. MVX5005 is currently completing formal IND-enabling studies, targeting clinical entry beginning Q3 2021 (phase 1a dose escalation with disease-specific expansion cohorts for monotherapy plus phase 1b combination chemotherapy and immunotherapy).

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET.

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.